Journal of Pharmacy Technology最新文献

{"title":"A Rare Case of Myopathy Associated with Entecavir Initiation.","authors":"Courtney Overton, Logan Brock, Bindu Betapudi, Drew A Wells","doi":"10.1177/87551225251382411","DOIUrl":"10.1177/87551225251382411","url":null,"abstract":"<p><p>Hepatitis B virus (HBV) infection can lead to severe complications, including cirrhosis, hepatocellular carcinoma, and death. Entecavir, a guanosine nucleoside analogue, is recommended for chronic hepatitis B virus (CHB) and is rarely associated with myopathy. This report presents a 65-year-old woman with CHB who developed suspected entecavir-associated myopathy. The patient, with a history of hypertension, systemic lupus erythematosus, rheumatoid arthritis, seizures, stroke, polyneuropathy, cervical and lumbar myelopathy, bilateral lumbar radiculopathy, and alcohol use, was admitted for chest pain. Acute pathologies were ruled out; however, acute reactivation of CHB was identified. Entecavir was initiated, but the patient developed significant fatigue and muscle weakness within days, in the absence of acute liver failure. On discontinuation of entecavir and initiation of tenofovir disoproxil fumarate, the patient's symptoms improved. This case highlights the rare but serious adverse effects of entecavir, emphasizing the need for careful monitoring and consideration of alternative treatments in patients with CHB.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251382411"},"PeriodicalIF":1.3,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Interactions With Excessive Daytime Sleepiness Treatments.","authors":"Stanley V Thomas, Mark A Malesker, Daniel E Hilleman, Naresh A Dewan","doi":"10.1177/87551225251369328","DOIUrl":"10.1177/87551225251369328","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the potential for drug interactions with pharmacotherapy for central hypersomnolence (modafinil, armodafinil, solriamfetol, pitolisant, sodium oxybate, methylphenidate, amphetamine, lithium, clarithromycin). <b>Data Sources:</b> A systemic literature search (1980 to June 2025) was performed using PUBMED, SCOPUS, and EMBASE to locate relevant articles. The MeSH terms included specific medication and \"drug interactions.\" DAILYMED was used for product-specific interactions. <b>Study Selection and Data Extraction:</b> The search was conducted to identify drug interactions with excessive daytime sleepiness treatments. The search was limited to those articles studying humans and publications using the English language. Case reports, clinical trials, review articles, treatment guidelines, and package labeling were selected for inclusion. <b>Data Synthesis:</b> Primary literature and package labeling indicate that pharmacotherapy for central hypersomnolence is subject to both pharmacokinetic and pharmacodynamic interactions. While some interactions can be clinically significant, much of the data available for potential drug interactions was found in the package labeling and not from the primary literature. <b>Conclusions:</b> Available literature indicates that pharmacotherapy for central hypersomnolence is associated with clinically significant drug interventions and subsequent possible adverse reactions. Clinicians in all practice settings should be mindful of the potential to minimize drug interactions and optimize pharmacotherapy for hypersomnolence.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251369328"},"PeriodicalIF":1.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12496447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Risk of Intracranial Hemorrhage With Tenecteplase Versus Alteplase in Acute Ischemic Stroke.","authors":"Katherine Hammaker, Stephanie Bills, Taylor H Cason, Nicholas J Quinn, Rhonda Cadena, Alyssa Lear","doi":"10.1177/87551225251377987","DOIUrl":"10.1177/87551225251377987","url":null,"abstract":"<p><p><b>Background:</b> In patients with acute ischemic stroke (AIS), tenecteplase and alteplase help preserve brain tissue. The 2019 American Heart Association/American Stroke Association guidelines designate alteplase as the first-line therapy for AIS, listing tenecteplase as a reasonable alternative for patients eligible for mechanical thrombectomy. The 2023 European Stroke Organisation recommends tenecteplase in patients with AIS due to large vessel occlusion prior to thrombectomy. Our institution adopted tenecteplase as the formulary fibrinolytic for AIS due to emerging clinical data, reduced cost, and operational benefits. <b>Objective:</b> The objective was to compare outcomes associated with tenecteplase versus alteplase in AIS. <b>Methods:</b> This multicenter, retrospective study included adults treated with tenecteplase or alteplase for AIS between April 1, 2022 and April 1, 2023. The primary outcome was intracranial hemorrhage (ICH) within 36 hours. Secondary outcomes included hospital and intensive care unit length of stay, in-hospital all-cause mortality, door-to-needle time, time to reperfusion, and adverse events. A subgroup analysis was performed to assess ICH that required reversal therapies. <b>Results:</b> There was no significant difference in the incidence of ICH between the tenecteplase and alteplase groups (20.4% vs 11.7%; <i>P</i> = 0.09). Within the subgroup analysis, a higher proportion of patients in the tenecteplase group required reversal therapies for ICH compared with the alteplase group (35.0% vs 8.3%; <i>P</i> = 0.09). Secondary outcomes were similar between groups. <b>Conclusion</b>: There was no significant difference in the incidence of ICH after tenecteplase or alteplase administration. Further studies are warranted to clarify the comparative safety profiles of tenecteplase and alteplase.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251377987"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145232765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extending Universal Licensing Recognition (ULR) Laws to Licensure Renewal: A Pharmacist Case Study.","authors":"Alex Adams, Edward J Timmons","doi":"10.1177/87551225251375346","DOIUrl":"10.1177/87551225251375346","url":null,"abstract":"<p><p>Universal Licensing Recognition (ULR) laws have emerged as a key policy tool to improve license mobility by allowing licensure obtained in one state to be more easily recognized in another. While these reforms have increased access to licensure and employment opportunities, they generally apply only to initial licensure, not to renewal. Nearly all state boards of pharmacy require continuing education (CE) for license renewal, yet CE requirements vary significantly across states in terms of hours, topics, formats, reporting frequency, and approved providers. These discrepancies create substantial administrative burdens for pharmacists maintaining active licenses in multiple jurisdictions. This article examines the implications of extending ULR principles to license renewal, using a case study of a pharmacist licensed in West Virginia and neighboring states. The analysis suggests that pharmacists working across state lines often default to the most restrictive CE standards to ensure compliance, incurring unnecessary cost and complexity. We highlight Idaho's 2024 reform to its ULR statute, which exempts multistate licensees from duplicative CE requirements if they comply with their home state's CE standards and limits overall CE burdens based on regional averages. These reforms offer a promising model for pharmacy regulators seeking to reduce administrative friction, support workforce flexibility, and enhance access to care without compromising professional standards.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251375346"},"PeriodicalIF":1.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Therapeutic Plasma Exchange on Apixaban Plasma Levels.","authors":"David Hensler, Danielle Burghardt","doi":"10.1177/87551225251369344","DOIUrl":"10.1177/87551225251369344","url":null,"abstract":"<p><p><b>Objective:</b> Therapeutic plasma exchange (TPE) may enhance the elimination of drugs from human plasma. Removal of apixaban during TPE has not been extensively described previously. <b>Case:</b> This is a retrospective report of a 76-year-old man admitted to the hospital on apixaban with acute worsening of respiratory and bulbar symptoms due to myasthenia gravis. On hospital day (HOD) 1, TPE was initiated for management of myasthenic crisis. Apixaban levels were obtained before and after a TPE session on HOD 3. On HOD 3, the patient's apixaban plasma level decreased from 88 ng/mL before TPE to 81 ng/mL after. Apixaban displayed an elimination half-life of 65.5 hours with intervening TPE. <b>Discussion/conclusions:</b> We report no clinically significant apixaban removal in a patient undergoing TPE for myasthenic crisis. This differs from previous reports. Supplemental dosing or rescheduling of apixaban doses around TPE sessions may be unnecessary, though more data are needed.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251369344"},"PeriodicalIF":1.3,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct Oral Anticoagulant Transition Strategies Using Anti-Xa Concentrations Upon Intensive Care Unit Admission.","authors":"Mariah I Sigala, Corey V Dinunno, Chelsea N Lopez, Luma Succar, Jenny H Petkova, Edward A Graviss, Duc T Nguyen, Kevin R Donahue","doi":"10.1177/87551225251372486","DOIUrl":"10.1177/87551225251372486","url":null,"abstract":"<p><p><b>Background:</b> The increased utilization of oral factor Xa inhibitors (FXaI) has led to a growing interest in the clinical utility of FXaI-specific anti-Xa concentrations. Critically ill populations are at risk of bleeding secondary to FXaI accumulation in the setting of end-organ dysfunction. To mitigate this risk, an FXaI anti-Xa concentration-guided approach to transitioning between oral and parenteral anticoagulation has been explored. <b>Objective:</b> To compare the incidence of bleeding upon intensive care unit (ICU) admission between 2 different FXaI transition strategies: concentration versus non-concentration-guided. <b>Methods:</b> We performed a retrospective chart review of patients admitted between January 2019 and May 2022 with objective evidence of FXaI exposure within 48 hours preceding ICU admission. Patients were excluded if they were admitted to the ICU with a primary diagnosis related to a bleeding event, received a non-FXaI anticoagulant 48 hours preceding ICU admission, remained off anticoagulation during their ICU admission, or underwent surgical procedures. The primary outcome was the incidence of major bleeding within 5 days of ICU admission. Thromboembolic events were evaluated as a secondary endpoint. <b>Results:</b> A total of 433 patients (184 concentration-guided vs 249 non-concentration-guided) were included. There was no difference in major bleeding between groups (2.7% in concentration-guided vs 3.6% in non-concentration-guided; <i>P</i> = 0.79). Thromboembolic complications were similar between groups (1.6% in concentration-guided vs 2.0% in non-concentration-guided; <i>P</i> = 1.00) despite a longer time from last FXaI dose to anticoagulant transition in the concentration-guided group (29.9 hours vs 19.4 hours; <i>P</i> < 0.01). <b>Conclusion and relevance:</b> Use of FXaI concentrations to guide anticoagulation transition in the ICU had no impact on major bleeding events or thromboembolic complications. Further analyses are needed to validate FXaI concentration-guided strategies and solidify anti-Xa cutoffs to create a standardized approach to FXaI transitions in the critically ill patient population.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251372486"},"PeriodicalIF":1.3,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of an Interruptive Alert on the Number of Women Receiving CDC-Recommended Therapy for Trichomoniasis.","authors":"Nicole Sunshine, Rachel M Kenney, Nathan A Everson, Christen J Arena, Erin Eriksson, Brian M Church, Jacob Manteuffel, Michael P Veve","doi":"10.1177/87551225251369348","DOIUrl":"10.1177/87551225251369348","url":null,"abstract":"<p><p><b>Background:</b> The 2021 Centers of Disease Control and Prevention (CDC) sexually transmitted infection treatment guidelines recommend a 7-day course of metronidazole or single-dose tinidazole for women with trichomoniasis due to improved patient outcomes compared with single-dose metronidazole therapy. A health system antimicrobial stewardship program implemented an interruptive electronic health record (EHR) alert to promote optimal trichomoniasis prescribing when nonrecommended treatment is ordered. <b>Objective:</b> To determine the impact of an interruptive EHR alert on optimal trichomoniasis prescribing for women. <b>Methods:</b> This was an institutional review board-approved, single pretest, posttest quasi-experiment of women ≥15 years with a microbiologically confirmed <i>Trichomonas vaginalis</i> infection from 10/2023 to 12/2023 (preintervention) and 10/2024 to 12/2024 (postintervention). An EHR alert was implemented 9/2024 that notifies prescribers that single-dose metronidazole 2 g is not recommended and suggests CDC-recommended treatments. The primary outcome was the proportion of single-dose metronidazole 2 g orders before and after EHR alert implementation. A secondary cross-sectional evaluation of all alerts triggered from 10/2024 to 12/2024 was performed and included the number of alerts, location of alert, and provider response. <b>Results:</b> A total of 285 patients were included, 49.8% pre-intervention and 50.2% postintervention. Metronidazole 2 g was prescribed for 8.45% of pre-intervention and 2.80% of postintervention patients (<i>P</i> = 0.038). The clinical support alert fired 102 times for 75 patients during the 3-month postimplementation period. The alert was associated with a change in intended prescription to a metronidazole 7-day course in greater than 60% of patients over 3 months. <b>Conclusion:</b> The implementation of an interruptive alert was associated with high acceptance and improved prescribing for women treated for trichomoniasis.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251369348"},"PeriodicalIF":1.3,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Doxycycline for <i>Legionella</i> Pneumonia: Expanding Treatment Horizons Through a Case Series and Narrative Review.","authors":"M Gabriela Cabanilla, Aileen C Scheibner, Jorge R Mera","doi":"10.1177/87551225251366324","DOIUrl":"10.1177/87551225251366324","url":null,"abstract":"<p><p><b>Background:</b> <i>Legionella</i> pneumonia is a significant cause of community-acquired pneumonia that often requires timely and effective treatment. While fluoroquinolones and macrolides are the recommended first-line therapies, doxycycline offers an alternative with favorable pharmacokinetics, safety, and minimal drug-drug interactions. <b>Methods:</b> We describe three hospitalized patients with <i>Legionella</i> pneumonia who received doxycycline monotherapy.Clinical outcomes, including symptom resolution and survival, were assessed at 60 days. A literature review was also performed for studies published between 1980 and 2025 that evaluated doxycycline for Legionella infection. <b>Results:</b> All three patients achieved clinical improvement with doxycycline monotherapy, with resolution of presenting symptoms and survival at 60 days post-hospitalization. The literature review identified limited clinical data on doxycycline for Legionella pneumonia. In vitro data suggested that doxycycline may have lower bactericidal activity than fluoroquinolones, although its pharmacological profile and tolerability support its consideration in select cases. <b>Conclusion</b>: Doxycycline monotherapy was associated with favorable outcomes in three cases of Legionella pneumonia. Although the evidence remains sparse, doxycycline may represent a viable alternative when first-line therapy is contraindicated. Further research is required to define its role in the treatment of <i>Legionella</i> pneumonia.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251366324"},"PeriodicalIF":1.3,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton Pump Inhibitor Use in Patients With Cirrhosis and Its Association With Spontaneous Bacterial Peritonitis.","authors":"Morgan Thomas, Cameron Lanier, Kelly Covert","doi":"10.1177/87551225251364516","DOIUrl":"https://doi.org/10.1177/87551225251364516","url":null,"abstract":"<p><p><b>Background:</b> Cirrhosis is a major cause of morbidity and mortality in the United States, with spontaneous bacterial peritonitis (SBP) being a serious complication. Established SBP risk factors include gastrointestinal bleeding and low ascitic protein, but the role of proton pump inhibitors (PPIs) remains unclear. <b>Objective:</b> This study evaluated the impact of PPI use on primary SBP development in hospitalized patients with cirrhosis. Additional objectives included reviewing PPI prescribing patterns and associated clinical outcomes. <b>Methods:</b> An institutional review board-approved, retrospective chart review was conducted on adults (≥18 years) with cirrhosis admitted for presumed SBP between June 1, 2022, and June 30, 2024. Exclusion criteria included pregnancy, incarceration, and recent or current upper gastrointestinal bleeding. Patients were grouped by PPI exposure, defined as PPI use prior to admission. The primary outcome was SBP incidence; secondary outcomes included mortality and hepatic decompensation events. <b>Results:</b> Eighty-one patients were included: 42 reported home PPI therapy, and 39 did not. SBP incidence was 33.3% in the PPI group versus 20.5% in the no PPI group (χ² = 0.249, <i>P</i> = 0.618). Worsening ascites occurred in 99%, encephalopathy in 42%, varices in 11%, and suspected hepatorenal syndrome in 21%. In-hospital mortality was 9.9%. PPI indications were often undocumented. <b>Conclusion and Relevance:</b> Although no significant association was found between home PPI use and SBP, frequent undocumented use and potential overuse of PPIs underscore the need for targeted intervention. Pharmacists are well-positioned to lead stewardship efforts by reviewing indications and minimizing unnecessary therapy to enhance safety and outcomes.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251364516"},"PeriodicalIF":1.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Intravenous Electrolyte Supplementation on Refeeding Syndrome for Patients Initiated on Parenteral Nutrition.","authors":"Makayla F Hoke, Katelyn A Butler, Marcos J Ortiz-Uriarte, Andrew J Franck","doi":"10.1177/87551225251363426","DOIUrl":"https://doi.org/10.1177/87551225251363426","url":null,"abstract":"<p><p><b>Background:</b> Refeeding syndrome (RS) is a potentially life-threatening condition, marked by decreases in serum phosphorus, potassium, or magnesium, that commonly occurs in patients who receive parenteral nutrition (PN) after a period of inadequate caloric intake. <b>Objective:</b> To compare the occurrence and severity of RS in hospitalized patients who received intravenous (IV) electrolyte supplementation versus those who did not receive IV electrolyte supplementation prior to initiation of PN. <b>Methods:</b> This single-center, retrospective cohort study included adult patients hospitalized over a 10-year period who received PN. The primary outcome was the occurrence of RS in each group (decrease in serum phosphorus, potassium, or magnesium of 10% or more from baseline within 5 days of PN initiation). <b>Results:</b> A total of 124 patients were included in the study, with 62 patients in each group. Fifty-two patients (83.9%) in the IV electrolyte supplementation group developed RS of any severity compared to 48 patients (77.4%) in the no IV electrolyte supplementation group (odds ratio [OR] = 1.52, 95% confidence interval [CI] = 0.62 to 3.74, <i>P</i> = 0.4). The IV electrolyte supplementation group developed more mild cases of RS (OR = 2.48, 95% CI = 1.14 to 5.40, <i>P</i> = 0.02), had a lower median decrease in serum phosphorus (median difference [MD] = -6.0, 95% CI = 10.9 to <-0.1, <i>P</i> = 0.03), and had lower in-hospital mortality (OR = 0.25, 95% CI = 0.09 to 0.74, <i>P</i> = 0.008). There were no significant differences for other secondary outcomes. <b>Conclusion:</b> Overall occurrence of RS was not significantly different between groups. However, some findings were suggestive of benefit associated with IV electrolyte supplementation.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251363426"},"PeriodicalIF":1.3,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144958309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}